Table 1.
Correlation between PEG10 expression and the clinicopathologic features in 218 hepatocellular carcinomas
| Variable | No. | PEG10 expression | p-value |
|---|---|---|---|
| Age (yr) | 0.046 | ||
| ≤ 55 | 130 | 95 (73.1) | |
| > 55 | 88 | 53 (60.2) | |
| Gender | 0.037 | ||
| Female | 39 | 32 (82.1) | |
| Male | 179 | 116 (64.8) | |
| Tumor size (cm) | 0.772 | ||
| ≤ 5.0 | 134 | 90 (67.2) | |
| > 5.0 | 84 | 58 (69.0) | |
| Edmondson grade | 0.021 | ||
| I | 18 | 8 (44.4) | |
| II | 151 | 101 (66.9) | |
| III | 49 | 39 (79.6) | |
| Microvascular invasion | 0.001 | ||
| (-) | 94 | 52 (55.3) | |
| (+) | 124 | 96 (77.4) | |
| Major portal vein invasion | 0.730 | ||
| (-) | 208 | 142 (68.3) | |
| (+) | 10 | 6 (60.0) | |
| Intrahepatic metastasis | 0.008 | ||
| (-) | 162 | 102 (63.0) | |
| (+) | 56 | 46 (82.1) | |
| Multicentric occurrence | > 0.999 | ||
| (-) | 209 | 142 (67.9) | |
| (+) | 9 | 6 (66.7) | |
| AJCC T-stage | 0.011 | ||
| 1 | 91 | 51 (56.0) | |
| 2 | 85 | 64 (75.3) | |
| 3 | 39 | 31 (79.5) | |
| 4 | 3 | 2 (66.7) | |
| BCLC stage | 0.390 | ||
| 0-A | 115 | 74 (64.3) | |
| B | 92 | 67 (72.8) | |
| C | 11 | 7 (63.6) | |
| Albumin level (g/dL) | 0.240 | ||
| > 3.5 | 191 | 127 (66.5) | |
| ≤ 3.5 | 27 | 21 (77.8) | |
| AFP level (ng/mL)a) | < 0.001 | ||
| ≤ 200 | 126 | 70 (55.6) | |
| > 200 | 84 | 73 (86.9) | |
| Etiology | 0.114 | ||
| Non-viral | 27 | 15 (55.6) | |
| HBV | 171 | 122 (71.3) | |
| HCV | 20 | 11 (55.0) | |
| Liver cirrhosis | 0.102 | ||
| (-) | 107 | 67 (62.6) | |
| (+) | 111 | 81 (73.0) | |
| Early recurrence (≤ 2 yr) | < 0.001 | ||
| (-)b) | 61 | 32 (52.5) | |
| (+) | 122 | 97 (79.5) | |
| Late recurrence (> 2 yr) | 0.863 | ||
| (-)b) | 61 | 32 (52.5) | |
| (+) | 35 | 19 (54.3) |
Values are presented as number (%). PEG10, paternally expressed gene 10; AJCC, American Joint Committee on Cancer; BCLC, Barcelona Clinic Liver Cancer; AFP, α-fetoprotein; HBV, hepatitis B virus; HCV, hepatitis C virus.
a)
Partial data were not available,
b)
No early or late recurrence.